Evidence map›Paper›PMID 35884572›Full record

ArticleCancers2022

Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.

Carmen Herrero Vicent, Xavier Tudela, Paula Moreno Ruiz, Víctor Pedralva, Ana Jiménez Pastor, Daniel Ahicart, Silvia Rubio Novella, Isabel Meneu, Ángela Montes Albuixech, Miguel Ángel Santamaria and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Carmen Herrero VicentMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Xavier TudelaRadiodiagnosis Department, The Provincial Hospital of Castellon, 12100 Castellon, Spain.
Paula Moreno RuizQuantitative Imaging Biomarkers in Medicine (Quibim), 46021 Valencia, Spain.ORCID 0000-0003-2138-6988
Víctor PedralvaRadiodiagnosis Department, The Provincial Hospital of Castellon, 12100 Castellon, Spain.
Ana Jiménez PastorQuantitative Imaging Biomarkers in Medicine (Quibim), 46021 Valencia, Spain.ORCID 0000-0002-0978-9429
Daniel AhicartRadiodiagnosis Department, The Provincial Hospital of Castellon, 12100 Castellon, Spain.
Silvia Rubio NovellaMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Isabel MeneuRadiodiagnosis Department, The Provincial Hospital of Castellon, 12100 Castellon, Spain.
Ángela Montes AlbuixechMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Miguel Ángel SantamariaRadiodiagnosis Department, The Provincial Hospital of Castellon, 12100 Castellon, Spain.
María FonfriaMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Almudena Fuster-MatanzoQuantitative Imaging Biomarkers in Medicine (Quibim), 46021 Valencia, Spain.
Santiago Olmos AntónMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Eduardo Martínez de DueñasMedical Oncology Department, The Provincial Hospital of Castellon, 12002 Castellon, Spain.
Fundación Hospital Provincial de Castellón · ES

Funding

Fundación Hospital Provincial de Castellón CAF 21-018
6 · The paper itself

Abstract

backgroundMost breast cancer (BC) patients fail to achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). The aim of this study was to evaluate whether imaging features (perfusion/diffusion imaging biomarkers + radiomic features) extracted from pre-treatment multiparametric (mp)MRIs were able to predict, alone or in combination with clinical data, pCR to NAC.

methodsPatients with stage II-III BC receiving NAC and undergoing breast mpMRI were retrospectively evaluated. Imaging features were extracted from mpMRIs performed before NAC. Three different machine learning models based on imaging features, clinical data or imaging features + clinical data were trained to predict pCR. Confusion matrices and performance metrics were obtained to assess model performance. Statistical analyses were conducted to evaluate differences between responders and non-responders.

resultsFifty-eight patients (median [range] age, 52 [45-58] years) were included, of whom 12 showed pCR. The combined model improved pCR prediction compared to clinical and imaging models, yielding 91.5% of accuracy with no false positive cases and only 17% false negative results. Changes in different parameters between responders and non-responders suggested a possible increase in vascularity and reduced tumour heterogeneity in patients with pCR, with the percentile 25th of time-to-peak (TTP), a classical perfusion parameter, being able to discriminate both groups in a 75% of the cases.

conclusionsA combination of mpMRI-derived imaging features and clinical variables was able to successfully predict pCR to NAC. Specific patient profiles according to tumour vascularity and heterogeneity might explain pCR differences, where TTP could emerge as a putative surrogate marker for pCR.

Indexed as

imaging biomarkersmachine learningmultiparametric MRIradiomics

Identifiers

PMID35884572
PMCPMC9317428
OpenAlexW4286214471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.